Welcome to Paid Research Studies




  • Condition:   Smoking
    Interventions:   Other: Brussel Sprouts;   Drug: Deuterated Phenanthrene
    Sponsor:   University of Minnesota - Clinical and Translational Science Institute
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melphalan;   Drug: Bortezomib
    Sponsor:   Hackensack Meridian Health
    Recruiting

  • Conditions:   Pulmonary Disease, Chronic Obstructive;   Congestive Heart Failure
    Intervention:   Other: sip feeding with stable isotope infusion
    Sponsor:   Texas A&M University
    Recruiting

  • Conditions:   Obesity;   Surgery
    Intervention:   Other: Stable isotope infusion
    Sponsor:   Texas A&M University
    Recruiting

  • Conditions:   Muscle Atrophy;   Quality of Life
    Interventions:   Drug: Essential Amino Acids (EAA);   Drug: Placebo (Alanine)
    Sponsors:   University of Oregon;   Slocum Center for Orthopedics and Sports Medicine;   Slocum Research & Education Foundation;   Oregon Research Institute;   Oregon Health and Science University;   University of Arkansas;   National Institute on Aging (NIA)
    Recruiting

  • Condition:   Phenylketonuria
    Interventions:   Drug: saproterin dihydrochloride;   Other: Diet treatment
    Sponsors:   University Hospitals Cleveland Medical Center;   BioMarin Pharmaceutical
    Recruiting

  • Condition:   Neuroendocrine Tumors
    Intervention:   Drug: [90]Y-DOTATOC
    Sponsors:   Sandeep Laroia;   National Institutes of Health (NIH);   Holden Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pulmonary Disease, Chronic Obstructive
    Interventions:   Other: stable amino acid infusion;   Other: acute exercise with amino acid infusion;   Other: 24-hour post exercise amino acid infusion
    Sponsor:   Texas A&M University
    Recruiting

  • Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Dietary Supplement: Capsule + Powder supplementation;   Other: stable tracer infusion
    Sponsor:   Texas A&M University
    Recruiting

  • Condition:   Glioma
    Interventions:   Drug: Fluorine F 18 Fluorodopa;   Radiation: Intensity-Modulated Radiation Therapy;   Procedure: Positron Emission Tomography
    Sponsor:   Mayo Clinic
    Recruiting

  • Condition:   Phenylketonuria
    Interventions:   Radiation: Preparative Radiation Therapy;   Procedure: Hepatocyte Transplant;   Drug: Immunosuppression;   Other: Liver Evaluation;   Behavioral: Neuro-psychological Assessment;   Diagnostic Test: Whole body Phe oxidation testing;   Procedure: Liver Biopsy
    Sponsor:   Ira Fox
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Crohn's Disease
    Interventions:   Biological: autologous CD34-selected peripheral blood stem cells transplant;   Drug: Alemtuzumab;   Drug: ATG;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: G-CSF;   Drug: Mesna
    Sponsor:   Paul Szabolcs
    Recruiting

  • Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Blinatumomab;   Procedure: Autologous stem cell transplant;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral blood draws
    Sponsors:   Washington University School of Medicine;   Amgen
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   HLA-DP4 Positive Cells Present;   Platinum-Resistant Ovarian Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
    Interventions:   Biological: Aldesleukin;   Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes;   Other: Cellular Therapy;   Drug: Melphalan
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Plasma Cell Myeloma;   Secondary Amyloidosis
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Melphalan;   Biological: Daratumumab;   Other: Laboratory Biomarker Analysis
    Sponsors:   City of Hope Medical Center;   Janssen, LP
    Recruiting

  • Conditions:   Phenylketonuria;   Hyperphenylalaninaemia
    Intervention:   Drug: Kuvan
    Sponsor:   BioMarin Pharmaceutical
    Recruiting

  • Conditions:   Phenylketonurias;   PAH Deficiency
    Intervention:   Genetic: HMI-102
    Sponsor:   Homology Medicines, Inc
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS;   Drug: Sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: Mycophenolate mofetil
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin;   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting

  • Conditions:   Breast Carcinoma;   Estrogen Receptor Positive
    Interventions:   Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography;   Device: Investigational software and coils in PET/MR scan
    Sponsors:   Andrei Iagaru;   General Electric
    Recruiting

  • Conditions:   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
    Interventions:   Procedure: Computed Tomography;   Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
    Sponsor:   Andrei Iagaru
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Transformed Indolent Non-Hodgkin Lymphoma
    Interventions:   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Venetoclax
    Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Plasma Cell Leukemia;   Plasmacytoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Panobinostat;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Oligoastrocytoma;   Recurrent Adult Brain Neoplasm
    Interventions:   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mannitol;   Drug: Melphalan;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Busulfan;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Olaparib;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacokinetic Study;   Biological: Rituximab;   Drug: Vorinostat
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aplastic Anemia;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Secondary Myelofibrosis;   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Blasts 15 Percent or Less of Bone Marrow Nucleated Cells;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Bendamustine Hydrochloride;   Drug: Cyclophosphamide;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   B Acute Lymphoblastic Leukemia;   CD22 Positive;   Lymphocytic Neoplasm;   Lymphoma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Bendamustine;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Biological: Inotuzumab Ozogamicin;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Indolent Adult Non-Hodgkin Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Lenalidomide;   Drug: Melphalan;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Gene Mutations;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Acute Myeloid Leukemia With Variant MLL Translocations;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Chemotherapy-Related Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Gene Mutation;   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Allogeneic Natural Killer Cell Line NK-92;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Autoimmune Disease;   Neurologic Autoimmune Disease;   Autologous Transplant Autoimmune;   Multiple Sclerosis Transplant;   MS Stem Cell Transplant;   Multiple Sclerosis Stem Cell Transplant;   Stiff Person Syndrome;   HCT for Neurologic Autoimmune Disorders;   CIDP Transplant;   Myasthenia Gravis Transplant
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Prednisone;   Procedure: Syngeneic Bone Marrow Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   High-Risk Neuroblastoma;   NMYC Gene Amplification
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Drug: Isotretinoin;   Drug: Melphalan;   Biological: Sargramostim;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Vincristine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting